Company: INDP
Filing Date: 2025-01-31
Form Type: 8-K
Source: 0001493152-25-004428
Chunk: 0

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-01-31
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item       Notice                                                                                        

On
January 31, 2025, Indaptus Therapeutics, Inc. (the “ Company”) was notified (the “ Notification Letter”) by the
Nasdaq Listing Qualifications (“ Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in
Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities
to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum
bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price
of the Company’s common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company no
longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s
common stock on the Nasdaq Capital Market and, at this time, the common stock will continue to trade on the Nasdaq Capital Market under
the symbol “ INDP”.

The
Notification Letter provides that the Company has 180 calendar days, or until July 30, 2025, to regain compliance with Nasdaq Listing
Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00
per share for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by July 30, 2025, the Company
may then be eligible for additional 180 days if it meets the continued listing requirement for market value of publicly held shares and
all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to
provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for
the second compliance period or fails to regain compliance during the second compliance period, then Nasdaq will notify the Company of
its determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the delisting
determination to a Hearings Panel.

The
Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options,
including,